カテゴリー:未分類

New Topics

  • 2019.05.06

Obtained patent for human lactoferrin Fc fusion protein with improved stability, and hoped for drug discovery such as anticancer drug with few side effects 2017.01.29 Press release Obtained patent for human lactoferrin Fc fusion protein applicable to anti-cancer drug etc. with few side effects The research team of Prof. Atsushi Sato et al.,  Department of Applied Biology, Tokyo Institute of Technology (Kachikura-cho, Hachioji-shi, Tokyo ) collaborated with biotech company NRL Pharma Co., Ltd. Has acquired a patent (* 1) of human lactoferrin Fc fusion protein with improved stability in the body.  In the future, it is expected to be applied to cancer treatment drugs with few side effects, taking advantage of the high safety and physiological activity of lactoferrin. 【background】 Lactoferrin (hereinafter referred to as LF) contained in milk etc. is known as a protein that exhibits various physiological activities such as anti-tumor, anti-inflammatory and anti-oxidation. Cow-derived LF has already been used as a supplement (health food) and many health promoting effects have been reported. This research aims to be the first in the world to be commercialized, focusing on the various physiological activities of LF and the high safety used as food. In general, protein drugs have had the problem that their stability in the […]